Posted by Michael Wonder on 17 Apr 2025
uniQure announces FDA breakthrough therapy designation granted to AMT-130 for the treatment of Huntington’s disease
17 April 2025 - Breakthrough therapy designation based on clinical evidence from Phase I/II trials showing meaningful slowing of disease progression.
uniQure today announced that the US FDA has granted breakthrough therapy designation to AMT-130 for the treatment of Huntington’s disease, a rare, inherited neurodegenerative disorder for which there are currently no disease-modifying therapies available.
